332 related articles for article (PubMed ID: 27864628)
1. Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management.
Turner K; Samuel CA; Donovan HA; Beckjord E; Cardy A; Dew MA; van Londen GJ
Support Care Cancer; 2017 Apr; 25(4):1055-1061. PubMed ID: 27864628
[TBL] [Abstract][Full Text] [Related]
2. Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.
Samuel CA; Turner K; Donovan HAS; Beckjord E; Cardy A; Dew MA; van Londen GJ
Support Care Cancer; 2017 Dec; 25(12):3723-3731. PubMed ID: 28681126
[TBL] [Abstract][Full Text] [Related]
3. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
4. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
Lambert LK; Balneaves LG; Howard AF; Chia SLK; Gotay CC
Curr Oncol; 2021 Apr; 28(2):1472-1482. PubMed ID: 33918560
[TBL] [Abstract][Full Text] [Related]
6. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis.
Farias AJ; Ornelas IJ; Hohl SD; Zeliadt SB; Hansen RN; Li CI; Thompson B
Support Care Cancer; 2017 Jan; 25(1):75-83. PubMed ID: 27557832
[TBL] [Abstract][Full Text] [Related]
7. Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.
van Londen GJ; Donovan HS; Beckjord EB; Cardy AL; Bovbjerg DH; Davidson NE; Morse JQ; Switzer GE; Verdonck-de Leeuw IM; Dew MA
Oncol Nurs Forum; 2014 Nov; 41(6):660-8. PubMed ID: 25355021
[TBL] [Abstract][Full Text] [Related]
8. Trends in cancer survivors' experience of patient-centered communication: results from the Health Information National Trends Survey (HINTS).
Blanch-Hartigan D; Chawla N; Moser RP; Finney Rutten LJ; Hesse BW; Arora NK
J Cancer Surviv; 2016 Dec; 10(6):1067-1077. PubMed ID: 27193357
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
10. Patient-centered communication during oncology follow-up visits for breast cancer survivors: content and temporal structure.
Clayton MF; Dudley WN
Oncol Nurs Forum; 2009 Mar; 36(2):E68-79. PubMed ID: 19273396
[TBL] [Abstract][Full Text] [Related]
11. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
[TBL] [Abstract][Full Text] [Related]
12. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
[TBL] [Abstract][Full Text] [Related]
13. Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
Post KE; Ahmad Z; Jankauskaite G; Centracchio J; Oswald L; Horick N; Park ER; Temel JS; Greer JA; Jacobs J
J Pain Symptom Manage; 2024 Jan; 67(1):88-97. PubMed ID: 37816436
[TBL] [Abstract][Full Text] [Related]
14. Talking about sexual health during survivorship: understanding what shapes breast cancer survivors' willingness to communicate with providers.
Canzona MR; Fisher CL; Wright KB; Ledford CJW
J Cancer Surviv; 2019 Dec; 13(6):932-942. PubMed ID: 31741248
[TBL] [Abstract][Full Text] [Related]
15. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
[TBL] [Abstract][Full Text] [Related]
16. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
[TBL] [Abstract][Full Text] [Related]
17. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
[TBL] [Abstract][Full Text] [Related]
18. Providers' perceptions of communication breakdowns in cancer care.
Prouty CD; Mazor KM; Greene SM; Roblin DW; Firneno CL; Lemay CA; Robinson BE; Gallagher TH
J Gen Intern Med; 2014 Aug; 29(8):1122-30. PubMed ID: 24599795
[TBL] [Abstract][Full Text] [Related]
19. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
